NCT04803318招募中2 期
Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial
Second Affiliated Hospital of Guangzhou Medical University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2021年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.
研究概览
简要总结
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.
详细描述
The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Recurrent/Refractory advanced solid tumors
- •Age between 18 and 85 years
- •Expected life expectancy is greater than three months
排除标准
- •Benign tumor
- •Life expectancy is less than three months
- •Serious medical commodities
研究组 & 干预措施
Combination treatment of 3 inhibitors
Experimental
Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.
干预措施: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib (Drug)
结局指标
主要结局
Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.
时间窗: up to 36 months
次要结局
- Assessing overall survival(48 months)
- Assessing progress free survival(48 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaRenal Cell CarcinomaNCT02811861Eisai Inc.1,069
已完成
1 期
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadColorectal TumorsColorectal CancerColorectal CarcinomaColorectal NeoplasmNCT03377361Bristol-Myers Squibb325
已完成
1 期
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)Carcinoma, Renal CellNCT02454478Eisai Co., Ltd.7
进行中（未招募）
2 期
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerNCT05012371M.D. Anderson Cancer Center90
终止
3 期
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerNon Squamous, Non-small-cell Lung CancerNCT01244191Daiichi Sankyo1,048